Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEES phase II trial in castration-resistant prostate cancer
2010-021962-31Phase 2Active
- Sponsor
- Bo Lennernäs
- Start
- Jun 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketoconazole, etoposide, estramustine, cyclophosphamide and prednisolone in prostate cancer (PCa), sponsored by Bo Lennernäs. Primary endpoint: PSA response. Started Jun 2011; status: active.
02
Drugs
ketoconazoleetoposideestramustinecyclophosphamideprednisolone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2010-021962-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021962-31.